31 Nursing Care of Patients with Cardiac Disorders

Total Page:16

File Type:pdf, Size:1020Kb

31 Nursing Care of Patients with Cardiac Disorders 31 Nursing Care of Patients with Cardiac Disorders LEARNING OUTCOMES 1. Compare and contrast the etiology, pathophysiology, and 3. Discuss indications for and management of patients with manifestations of common cardiac disorders, including heart hemodynamic monitoring. failure, structural disorders, and inflammatory disorders. 4. Discuss the effects and nursing implications for medications 2. Explain risk factors and preventive measures for cardiac commonly prescribed for patients with cardiac disorders. disorders such as heart failure, inflammatory disorders, and 5. Describe nursing care for the patient undergoing cardiac valve disorders. surgery or cardiac transplant. CLINICAL COMPETENCIES 1. Apply knowledge of normal cardiac anatomy and physiology 5. Safely and knowledgeably administer prescribed medica- and assessment techniques in caring for patients with car- tions and treatments to patients with cardiac disorders. diac disorders. 6. Actively participate in planning and coordinating interprofes- 2. Assess the functional health status of patients with cardiac sional care for patients with cardiac disorders. disorders, documenting and reporting deviations for ex- 7. Provide appropriate teaching and community-based care for pected findings. patients with cardiac disorders and their families. 3. Based on patient assessment and knowledge of the disorder, 8. Evaluate the effectiveness of nursing care, revising the plan determine priority nursing diagnoses. of care as needed to promote, maintain, or restore the func- 4. Plan, prioritize, and provide evidence-based, individualized tional health status of patients with cardiac disorders. care for patients with cardiac disorders. MAJOR CHAPTER CONCEPTS • Heart failure, the most common cardiac disorder, is a condi- medication use including ACE inhibitors, beta-blockers, di- tion in which the heart is unable to pump effectively to meet uretics, and vasodilators to reduce the cardiac workload. the body’s needs for blood and oxygen to the tissues. • Nursing care of the patient with heart failure is primarily sup- • Heart failure is due to impaired myocardial contraction or portive and educative, providing the patient and family with excessive workload. the necessary knowledge and resources to manage this • Goals of heart failure management are to reduce the work- chronic condition. load and improve its function. Medical management includes KEY TERMS aortic valve, 950 mean arterial pressure paroxysmal nocturnal dyspnea rheumatic fever, 939 cardiac tamponade, 947 (MAP), 927 (PND), 924 rheumatic heart disease cardiomyopathy, 959 mitral valve, 950 pericarditis, 946 (RHD), 939 endocarditis, 941 murmur, 951 pulmonary edema, 935 stenosis, 939 heart failure, 920 myocarditis, 945 pulmonic valve, 950 tricuspid valve, 950 hemodynamics, 926 orthopnea, 924 regurgitation, 939 valvular heart disease, 950 Cardiac disorders affect the structure and/or function of the heart. failure and death. Emergence of symptoms (fatigue, dyspnea, chest These disorders interfere with the heart’s primary purpose: to pain) is common with the progression of cardiac disorders. The pump enough blood to meet the body’s demand for oxygen and New York Heart Association (NYHA) classification is commonly nutrients. Disruptions in cardiac function affect the functioning used to describe the severity of exertional symptoms observed of other organs and tissues, potentially leading to organ system (see Table 31–1). 919 DESIGN SERVICES OF # 151615 Cust: Pearson Au: LeMone Pg. No. 919 C/M/Y/K S4CARLISLE Title: Medical-Surgical Nursing: Critical Thinking in Patient Care 6e Short / Normal Publishing Services 920 Unit 8 • Responses to Altered Cardiovascular Function New York Heart Association Heart failure is the most common cardiac disorder. Other TABLE 31–1 Classification cardiac disorders discussed in this chapter include structural car- diac disorders, such as valve disorders and cardiomyopathy, and Class Severity of Symptoms inflammatory cardiac disorders, such as endocarditis and pericar- I No limitation in physical activity/asymptomatic ditis. Before continuing with this chapter, please review the heart’s II Symptoms with strenuous activity anatomy and physiology, nursing assessment, and diagnostic tests III Symptoms with mild activity in Chapter 29. IV Symptoms at rest Heart Failure Heart failure is a complex syndrome resulting from cardiac disor- prevalence of hypertension in African Americans contributes signifi- ders that impair the ventricles’ ability to fill with and effectively pump cantly to their risk for and incidence of heart failure. blood. In heart failure, the heart is unable to pump enough blood to meet the metabolic demands of the body. It is the end result of many Incidence, Prevalence, and Risk Factors conditions. Frequently, it is a long-term effect of coronary heart dis- More than 6.6 million people in the United States are currently living ease and myocardial infarction (MI) when left ventricular damage with heart failure; approximately 550,000 new cases of heart failure is extensive enough to impair cardiac output (refer to Chapter 29). are diagnosed annually (American Heart Association [AHA], 2013). Other diseases of the heart also may cause heart failure, including Estimates predict an additional 3 million people will have heart fail- structural and inflammatory disorders. In normal hearts, failure can ure by 2030. Its incidence and prevalence increase with age: Fewer result from excessive demands placed on the heart. Heart failure may than 5% of people between ages 55 and 64 have heart failure, whereas be acute or chronic. 6% to 10% of people ages 65 to 74 are affected. There is a rapid rise in heart failure prevalence after age 65. Those ages 75 to 84 have a 14.8 THE Patient WITH Heart FAILURE to 22.3/1000 person (per) years incidence, while those older than As mentioned, heart failure develops when the heart cannot effec- 85 years have a 32.7 to 41.9/1000 person-years incidence (see Nurs- tively fill or contract with adequate strength to function as a pump to ing Care of the Older Adult box). At age 40, the lifetime risk of devel- meet the needs of the body. As a result, cardiac output falls, leading oping heart failure is one in five (AHA, 2013). The estimated direct to decreased tissue perfusion. The body initially adjusts to reduced and indirect cost of heart failure in the United States in 2011 was cardiac output by activating inherent compensatory mechanisms $34.4 billion. The prevalence and mortality rate for heart failure is to restore tissue perfusion. These normal mechanisms may result higher in African Americans than in Whites. See the accompanying in vascular congestion—hence, the commonly used term congestive Focus on Cultural Diversity box. heart failure (CHF). As these mechanisms are exhausted, heart failure Ischemic heart disease (coronary heart disease) is the leading ensues, with increased morbidity and mortality. risk factor for heart failure. Up to 75% of individuals with heart failure Heart failure is a disorder of cardiac function. It frequently is due have a history of hypertension. to impaired myocardial contraction, which may result from coronary The prognosis for a patient with heart failure depends on its un- heart disease and myocardial ischemia or infarct or from a primary derlying cause and how effectively precipitating factors can be treated. cardiac muscle disorder such as cardiomyopathy or myocarditis. Most patients with heart failure die within 8 years of the diagnosis. The Structural cardiac disorders, such as valve disorders or congenital risk for sudden cardiac death is dramatically increased, occurring at a heart defects, and hypertension also can lead to heart failure when the rate six to nine times that of the general population. In 2009, one in heart muscle is damaged by the long-standing excessive workload as- nine death certificates in the United States mentioned heart failure as sociated with these conditions. Other patients without a primary ab- the primary or a contributing cause of death (AHA, 2013). normality of myocardial function may present with manifestations of heart failure due to acute excess demands placed on the myocardium, Physiology Review such as volume overload, hyperthyroidism, and massive pulmonary The mechanical pumping action of cardiac muscle propels the blood embolus (see Table 31–2). Hypertension and coronary heart disease it receives to the pulmonary and systemic vascular systems for reoxy- are the leading causes of heart failure in the United States. The high genation and delivery to the tissues. Cardiac output (CO) is the amount TABLE 31–2 Selected Causes of Heart Failure Impaired Myocardial Function Increased Cardiac Workload Acute Noncardiac Conditions • Coronary heart disease • Hypertension • Volume overload • Cardiomyopathies • Valve disorders • Hyperthyroidism • Rheumatic fever • Anemias • Fever, infection • Infective endocarditis • Congenital heart defects • Massive pulmonary embolus DESIGN SERVICES OF # 151615 Cust: Pearson Au: LeMone Pg. No. 920 C/M/Y/K S4CARLISLE Title: Medical-Surgical Nursing: Critical Thinking in Patient Care 6e Short / Normal Publishing Services Chapter 31 • Nursing Care of Patients with Cardiac Disorders 921 Explaining Physiologic Terms FOCUS ON CULTURAL DIVERSITY BOX 31–1 Using Practical Examples Heart Disease The concepts of preload, the Frank-Starling mechanism, compli- • Up to 6.6 million Americans have heart failure. Of these, about ance, and afterload can be difficult to understand and
Recommended publications
  • Guidelines on the Diagnosis and Management of Pericardial
    European Heart Journal (2004) Ã, 1–28 ESC Guidelines Guidelines on the Diagnosis and Management of Pericardial Diseases Full Text The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology Task Force members, Bernhard Maisch, Chairperson* (Germany), Petar M. Seferovic (Serbia and Montenegro), Arsen D. Ristic (Serbia and Montenegro), Raimund Erbel (Germany), Reiner Rienmuller€ (Austria), Yehuda Adler (Israel), Witold Z. Tomkowski (Poland), Gaetano Thiene (Italy), Magdi H. Yacoub (UK) ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Maria Angeles Alonso Garcia (Spain), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), Martin Cowie (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Enrique Fernandez Burgos (Spain), John Lekakis (Greece), Bertil Lindahl (Sweden), Gianfranco Mazzotta (Italy), Joa~o Morais (Portugal), Ali Oto (Turkey), Otto A. Smiseth (Norway) Document Reviewers, Gianfranco Mazzotta, CPG Review Coordinator (Italy), Jean Acar (France), Eloisa Arbustini (Italy), Anton E. Becker (The Netherlands), Giacomo Chiaranda (Italy), Yonathan Hasin (Israel), Rolf Jenni (Switzerland), Werner Klein (Austria), Irene Lang (Austria), Thomas F. Luscher€ (Switzerland), Fausto J. Pinto (Portugal), Ralph Shabetai (USA), Maarten L. Simoons (The Netherlands), Jordi Soler Soler (Spain), David H. Spodick (USA) Table of contents Constrictive pericarditis . 9 Pericardial cysts . 13 Preamble . 2 Specific forms of pericarditis . 13 Introduction. 2 Viral pericarditis . 13 Aetiology and classification of pericardial disease. 2 Bacterial pericarditis . 14 Pericardial syndromes . ..................... 2 Tuberculous pericarditis . 14 Congenital defects of the pericardium . 2 Pericarditis in renal failure . 16 Acute pericarditis . 2 Autoreactive pericarditis and pericardial Chronic pericarditis . 6 involvement in systemic autoimmune Recurrent pericarditis . 6 diseases . 16 Pericardial effusion and cardiac tamponade .
    [Show full text]
  • Final Program for the ATS International Conference Is Available in Printed and Digital Format
    WELCOME TO ATS 2017 • WASHINGTON, DC Welcome to ATS 2017 Welcome to Washington, DC for the 2017 American Thoracic Society International Conference. The conference, which is expected to draw more than 15,000 investigators, educators, and clinicians, is truly the destination for pediatric and adult pulmonary, critical care, and sleep medicine professionals at every level of their careers. The conference is all about learning, networking and connections. Because it engages attendees across many disciplines and continents, the ATS International Conference draws a large, diverse group of participants, a dedicated and collegial community that inspires each of us to make a difference in patients’ lives, now and in the future. By virtue of its size — ATS 2017 features approximately 6,700 original research projects and case reports, 500 sessions, and 800 speakers — participants can attend David Gozal, MD sessions and special events from early morning to the evening. At ATS 2017 there will be something for President everyone. American Thoracic Society Don’t miss the following important events: • Opening Ceremony featuring a keynote presentation by Nobel Laureate James Heckman, PhD, MA, from the Center for the Economics of Human Development at the University of Chicago. • Ninth Annual ATS Foundation Research Program Benefit honoring David M. Center, MD, with the Foundation’s Breathing for Life Award on Saturday. • ATS Diversity Forum will feature Eliseo J. Pérez-Stable, MD, Director, National Institute on Minority Health and Health Disparities at the National Institutes of Health. • Keynote Series highlight state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine.
    [Show full text]
  • The Pulmonary Manifestations of Left Heart Failure*
    The Pulmonary Manifestations of Left Heart Failure* Brian K. Gehlbach, MD; and Eugene Geppert, MD Determining whether a patient’s symptoms are the result of heart or lung disease requires an understanding of the influence of pulmonary venous hypertension on lung function. Herein, we describe the effects of acute and chronic elevations of pulmonary venous pressure on the mechanical and gas-exchanging properties of the lung. The mechanisms responsible for various symptoms of congestive heart failure are described, and the significance of sleep-disordered breathing in patients with heart disease is considered. While the initial clinical evaluation of patients with dyspnea is imprecise, measurement of B-type natriuretic peptide levels may prove useful in this setting. (CHEST 2004; 125:669–682) Key words: Cheyne-Stokes respiration; congestive heart failure; differential diagnosis; dyspnea; pulmonary edema; respiratory function tests; sleep apnea syndromes Abbreviations: CHF ϭ congestive heart failure; CSR-CSA ϭ Cheyne-Stokes respiration with central sleep apnea; CPAP ϭ continuous positive airway pressure; Dlco ϭ diffusing capacity of the lung for carbon monoxide; DM ϭ membrane conductance; FRC ϭ functional residual capacity; OSA ϭ obstructive sleep apnea; TLC ϭ total lung ϭ ˙ ˙ ϭ capacity; VC capillary volume; Ve/Vco2 ventilatory equivalent for carbon dioxide early 5 million Americans have congestive heart For a detailed review of the pathophysiology of N failure (CHF), with 400,000 new cases diag- high-pressure pulmonary edema, the reader is re- nosed each year.1 Unfortunately, despite the consid- ferred to several excellent recent reviews.2–4 erable progress that has been made in understanding the pathophysiology of pulmonary edema, the pul- monary complications of this condition continue to The Pathophysiology of Pulmonary challenge the bedside clinician.
    [Show full text]
  • Overview of Partial Left Ventriculectomy
    Prepared by ASERNIP-S NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of Partial Left Ventriculectomy Introduction This overview has been prepared to assist members of IPAC advise on the safety and efficacy of an interventional procedure previously reviewed by SERNIP. It is based on a rapid survey of published literature, review of the procedure by specialist advisors and review of the content of the SERNIP file. It should not be regarded as a definitive assessment of the procedure. Procedure name Partial Left Ventriculectomy The Batista Procedure Specialty society Society of Cardiothoracic Surgeons of Great Britain and Ireland Executive Summary Left partial ventriculectomy (PLV) seeks to treat dilated cardiomyopathy by reducing cardiac volume and hence heart wall pressure through the resection of a portion of the left ventricle. Patients receiving it are generally suitable for cardiac transplant but unable to receive it, often for social or economic reasons. PLV is an emerging procedure and the vast majority of evidence is case series, although there has been one retrospective comparative study of PLV and transplantation. Hospital mortality was reported for up to 30% of patients and overall mortality was around 40% of patients. Thirty day survival ranged from 50% to 99%, and no significant difference was found between PLV and transplant. One-year survival ranged from 46% to 80% and three- year survival was reported in one study as 60%. Event-free survival was reported as 80% at 30 days, 49% at 1 year and 26% at three years. Use of a left ventricular assist device or relisting for cardiac surgery was reported in one study at between 5% and 15% of patients at 30 days and in 43% at 1 year and 58% at 3 years.
    [Show full text]
  • Real-Time 3-Dimensional Echocardiography of the Heart 13 Years After Partial Left Ventriculectomy
    IMAGES IN CARDIOVASCULAR MEDICINE Print ISSN 1738-5520 / On-line ISSN 1738-5555 DOI 10.4070 / kcj.2010.40.6.295 Copyright ⓒ 2010 The Korean Society of Cardiology Open Access Real-Time 3-Dimensional Echocardiography of the Heart 13 Years After Partial Left Ventriculectomy Mi-Seung Shin, MD1, Tae Hoon Ahn, MD1, Ok Ryun Kim, RDCS1, Wook-Jin Chung, MD1, Woong Chol Kang, MD1, Kyoung Hoon Lee, MD1, Chan Il Moon, MD1, In Suck Choi, MD1, Eak Kyun Shin, MD1 and Chang Young Lim, MD2 1Division of Cardiology, Department of Internal Medicine, Gachon University, Gil Hospital, Incheon, 2Department of Thoracic and Cardiovascular Surgery, CHA University, Bundang CHA Hospital, Seongnam, Korea A 69-year-old woman diagnosed as having end-stage ure.2) Resection of the myocardium not only decreases dilated cardiomyopathy had undergone partial left ven- wall stress according to Laplace’s law, but may improve triculectomy (PLV) in 1996. This is the first reported stroke volume for sufficiently dilated and depressed ven- case of PLV (Batista procedure) in Korea.1) She was do- tricles. Using these operative techniques to alter the ing well under the New York Heart Association class II shape of the LV, in combination with optimal medical diagnosis in November 2009 and had received 3-dimen- management for heart failure, improves survival.3) Al- sional (3D) echocardiography for the evaluation of car- though a favorable outcome has been reported in se- diac function. lected patients, this method is currently not recommend- Full volume 3D echocardiography (Philips Medical, ed for treatment of heart failure because of high surgical IE33, Bothell, WA, USA) of the heart showed a dilated failure rates.4)5) Here, we report 3D echocardiographic left ventricle (LV) and gave a more accurate LV ejection findings of long-term survival of a patient who had un- fraction and time-volume curve during one cardiac cycle dergone a Batista procedure 13 years ago.
    [Show full text]
  • Medicare National Coverage Determinations Manual, Part 1
    Medicare National Coverage Determinations Manual Chapter 1, Part 1 (Sections 10 – 80.12) Coverage Determinations Table of Contents (Rev. 10838, 06-08-21) Transmittals for Chapter 1, Part 1 Foreword - Purpose for National Coverage Determinations (NCD) Manual 10 - Anesthesia and Pain Management 10.1 - Use of Visual Tests Prior to and General Anesthesia During Cataract Surgery 10.2 - Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post- Operative Pain 10.3 - Inpatient Hospital Pain Rehabilitation Programs 10.4 - Outpatient Hospital Pain Rehabilitation Programs 10.5 - Autogenous Epidural Blood Graft 10.6 - Anesthesia in Cardiac Pacemaker Surgery 20 - Cardiovascular System 20.1 - Vertebral Artery Surgery 20.2 - Extracranial - Intracranial (EC-IC) Arterial Bypass Surgery 20.3 - Thoracic Duct Drainage (TDD) in Renal Transplants 20.4 – Implantable Cardioverter Defibrillators (ICDs) 20.5 - Extracorporeal Immunoadsorption (ECI) Using Protein A Columns 20.6 - Transmyocardial Revascularization (TMR) 20.7 - Percutaneous Transluminal Angioplasty (PTA) (Various Effective Dates Below) 20.8 - Cardiac Pacemakers (Various Effective Dates Below) 20.8.1 - Cardiac Pacemaker Evaluation Services 20.8.1.1 - Transtelephonic Monitoring of Cardiac Pacemakers 20.8.2 - Self-Contained Pacemaker Monitors 20.8.3 – Single Chamber and Dual Chamber Permanent Cardiac Pacemakers 20.8.4 Leadless Pacemakers 20.9 - Artificial Hearts And Related Devices – (Various Effective Dates Below) 20.9.1 - Ventricular Assist Devices (Various Effective Dates Below) 20.10 - Cardiac
    [Show full text]
  • Appendix A: Surgical Procedure Terms and Definitions
    Appendix A: Surgical Procedure Terms and Definitions Anomalous Systemic Venous Connection Anomalous Systemic Venous Connection Repair Repair includes a range of surgical approaches, including, among others: ligation of anomalous vessels, reimplantation of anomalous vessels (with or without use of a conduit), or redirection of anomalous systemic venous flow through directly to the pulmonary circulation (bidirectional Glenn to redirect LSVC or RSVC to left or right pulmonary artery, respectively). Aortic Aneurysm Aortic aneurysm repair Aortic aneurysm repair by any technique. Aortic Dissection Aortic Dissection repair Aortic dissection repair by any technique. Aortic Root Replacement Aortic Root Replacement, Bioprosthetic Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) with a bioprosthesis (e.g., porcine) in a conduit, often composite. Aortic Root Replacement, Mechanical Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) with a mechanical prosthesis in a composite conduit. Aortic Root Replacement, Homograft Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) with a homograft Aortic Root Replacement, Valve sparing Replacement of the aortic root (that portion of the aorta attached to the heart; it gives rise to the coronary arteries) without replacing the aortic valve (using a tube graft). Aortic Valve Disease Ross Procedure Replacement of the aortic valve with a pulmonary autograft and replacement of the pulmonary valve with a homograft conduit. Konno Procedure (with and without aortic valve replacement) Relief of left ventricular outflow tract obstruction associated with aortic annular hypoplasia, aortic valvar stenosis and/or aortic valvar insufficiency via Konno aortoventriculoplasty.
    [Show full text]
  • 82044831.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector RESULTS AFTER PARTIAL LEFT VENTRICULECTOMY VERSUS HEART TRANSPLANTATION FOR IDIOPATHIC CARDIOMYOPATHY Steven W. Etoch, MD Objective: Partial left ventriculectomy has been introduced as an alterna- Steven C. Koenig, PhD tive surgical therapy to heart transplantation. We performed a single- Mary Ann Laureano, RN center, retrospective analysis of all patients with idiopathic dilated car- Pat Cerrito, PhD diomyopathy who underwent partial left ventriculectomy or heart Laman A. Gray, MD Robert D. Dowling, MD transplantation or who were listed for transplantation to determine operative mortality rate, 12-month survival, freedom from death on the heart transplantation waiting list, and freedom from death or need for relisting for heart transplantation. Methods: Patients who had partial left ventriculectomy (October 1996 to April 1998) were retrospectively com- pared with patients who were listed for heart transplantation (January 1995 to April 1998). Survival was assessed after the surgical procedure (partial left ventriculectomy vs heart transplantation) and from time of listing for heart transplantation to assess the additional impact of wait- ing list deaths. Freedom from death or relisting for heart transplanta- tion was also compared. Results: There was no difference in age or United Network for Organ Sharing status between the 2 groups. Twenty-nine patients with idiopathic dilated cardiomyopathy were listed for heart transplantation; 17 patients underwent transplantation, 6 patients died while on the waiting list, and 6 patients remain listed. One patient died after heart transplantation, and 1 patient required relisting. Sixteen patients had partial left ventriculectomy; 10 patients are in improved condition, 2 patients died (1 death early from sepsis and 1 death from progressive heart failure), and 4 patients required relisting for heart transplantation.
    [Show full text]
  • LCSH Section H
    H (The sound) H.P. 15 (Bomber) Giha (African people) [P235.5] USE Handley Page V/1500 (Bomber) Ikiha (African people) BT Consonants H.P. 42 (Transport plane) Kiha (African people) Phonetics USE Handley Page H.P. 42 (Transport plane) Waha (African people) H-2 locus H.P. 80 (Jet bomber) BT Ethnology—Tanzania UF H-2 system USE Victor (Jet bomber) Hāʾ (The Arabic letter) BT Immunogenetics H.P. 115 (Supersonic plane) BT Arabic alphabet H 2 regions (Astrophysics) USE Handley Page 115 (Supersonic plane) HA 132 Site (Niederzier, Germany) USE H II regions (Astrophysics) H.P.11 (Bomber) USE Hambach 132 Site (Niederzier, Germany) H-2 system USE Handley Page Type O (Bomber) HA 500 Site (Niederzier, Germany) USE H-2 locus H.P.12 (Bomber) USE Hambach 500 Site (Niederzier, Germany) H-8 (Computer) USE Handley Page Type O (Bomber) HA 512 Site (Niederzier, Germany) USE Heathkit H-8 (Computer) H.P.50 (Bomber) USE Hambach 512 Site (Niederzier, Germany) H-19 (Military transport helicopter) USE Handley Page Heyford (Bomber) HA 516 Site (Niederzier, Germany) USE Chickasaw (Military transport helicopter) H.P. Sutton House (McCook, Neb.) USE Hambach 516 Site (Niederzier, Germany) H-34 Choctaw (Military transport helicopter) USE Sutton House (McCook, Neb.) Ha-erh-pin chih Tʻung-chiang kung lu (China) USE Choctaw (Military transport helicopter) H.R. 10 plans USE Ha Tʻung kung lu (China) H-43 (Military transport helicopter) (Not Subd Geog) USE Keogh plans Ha family (Not Subd Geog) UF Huskie (Military transport helicopter) H.R.D. motorcycle Here are entered works on families with the Kaman H-43 Huskie (Military transport USE Vincent H.R.D.
    [Show full text]
  • ICD-9-CM Procedures (FY10)
    2 PREFACE This sixth edition of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) is being published by the United States Government in recognition of its responsibility to promulgate this classification throughout the United States for morbidity coding. The International Classification of Diseases, 9th Revision, published by the World Health Organization (WHO) is the foundation of the ICD-9-CM and continues to be the classification employed in cause-of-death coding in the United States. The ICD-9-CM is completely comparable with the ICD-9. The WHO Collaborating Center for Classification of Diseases in North America serves as liaison between the international obligations for comparable classifications and the national health data needs of the United States. The ICD-9-CM is recommended for use in all clinical settings but is required for reporting diagnoses and diseases to all U.S. Public Health Service and the Centers for Medicare & Medicaid Services (formerly the Health Care Financing Administration) programs. Guidance in the use of this classification can be found in the section "Guidance in the Use of ICD-9-CM." ICD-9-CM extensions, interpretations, modifications, addenda, or errata other than those approved by the U.S. Public Health Service and the Centers for Medicare & Medicaid Services are not to be considered official and should not be utilized. Continuous maintenance of the ICD-9- CM is the responsibility of the Federal Government. However, because the ICD-9-CM represents the best in contemporary thinking of clinicians, nosologists, epidemiologists, and statisticians from both public and private sectors, no future modifications will be considered without extensive advice from the appropriate representatives of all major users.
    [Show full text]
  • 42 Pericardiocentesis (Perform) 341
    PROCEDURE Pericardiocentesis (Perform) 42 Kathleen M. Cox PURPOSE: Pericardiocentesis is the removal of excess fl uid from the pericardial sac for identifi cation of the etiology of pericardial effusion by fl uid analysis (diagnostic pericardiocentesis) and/or prevention or treatment of cardiac tamponade (therapeutic pericardiocentesis). result of trauma, myocardial infarction, or iatrogenic PREREQUISITE NURSING injury, whereas chronic effusions can result from condi- KNOWLEDGE tions such as bacterial or viral pericarditis, cancer, autoim- mune disorders, uremia, etc. 2 With a decrease in cardiac • Advanced cardiac life support (ACLS) knowledge and output, the patient often develops chest pain, dyspnea, skills are required. tachycardia, tachypnea, pallor, cyanosis, impaired cere- • Knowledge and skills related to sterile technique are bral and renal function, diaphoresis, hypotension, neck needed. vein distention, distant or faint heart sounds, and pulsus • Clinical and technical competence in the performance of paradoxus. 4 pericardiocentesis is required. • The amount of fl uid in the pericardium is evaluated • Knowledge of cardiovascular anatomy and physiology is through chest radiograph, two-dimensional echocardio- needed. gram, electrocardiography (ECG), and clinical fi ndings. • The pericardial space normally contains 20–50 mL of Chest x-rays may not be diagnostically signifi cant in fl uid. patients with acute traumatic tamponade. 6 • Pericardial fl uid has electrolyte and protein profi les similar • Pericardiocentesis to remove fl uid from the pericardial to plasma. sac is performed therapeutically to relieve tamponade or • Pericardial effusion is generally defi ned as the accumula- to diagnose the etiology of the effusion. An acute tampon- tion of fl uid within the pericardial sac that exceeds the ade resulting in hemodynamic instability necessitates an stretch capacity of the pericardium, generally more than emergency procedure.
    [Show full text]
  • Icd-9-Cm (2010)
    ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular
    [Show full text]